Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Flublok® Influenza Vaccine Now Available!

November 13, 2013

Ready for Immediate Delivery

MERIDEN, Conn., Nov. 13, 2013 /PRNewswire/ — Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available. Quantities of Flublok are limited and will be distributed on a first-come, first-served basis exclusively by FFF Enterprises.

Flublok, a cutting-edge class of influenza vaccine called RIV3 (recombinant hemagglutinin influenza vaccine, trivalent formulation), is made by making just the active ingredient needed for protection without growing influenza virus. The vaccine contains 3 times the protective ingredient in traditional flu vaccines.

The CDC recommends the use of Flublok for all adults 18-49 years old and specifically for those in that age range who have a known or suspected egg allergy, regardless of severity.

To order Flublok, contact FFF Enterprises at (800) 843-7477 or online at www.MyFluVaccine.com.

Important Safety Information
Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.

Flublok should not be administered to anyone with a severe allergic reaction (e.g., anaphylaxis) to any vaccine component.

Tell the doctor if you have ever experienced Guillain-Barre syndrome (severe muscle weakness) within 6 weeks of receipt of a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your healthcare professional immediately. Vaccination with Flublok may not protect all individuals.

Please see the complete Package Insert available at www.Flublok.com or call 203-686-0800 for more information.

SOURCE Protein Sciences Corporation


Source: PR Newswire